ClinicalTrials.gg
RecruitingNCT04477590MMETUpdated Aug 25, 2023

Interactions of Medicine and Exercise With Meal Timing

An interventional study of EXERCISE TRAINING WITH OR WITHOUT MEDICATION in Metabolic Syndrome, Protection Against, Exercise Training and Metformin, sponsored by University of Castilla-La Mancha. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by University of Castilla-La Mancha · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Metabolic Syndrome with a site in Spain — 15 open to participants now, 21 under way, none of them phase 3. Metabolic Syndrome · Spain.

Planned enrollment
16th of 78
160 · median 61
Started
2022
with 5 others
No phase
66 of 89
13 open now
Primary completion
2024-05
later than 2 of 20 live
Registered
48th of 89
by date
Lead sponsor
5 of 89
University of Castilla-La Mancha

Among the 89 studies in Metabolic Syndrome with a site in Spain, this one is the 16th largest by planned enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2022, is one of 66 with no phase, reaches primary completion later than 2 of the 20 other live ones, and was the 48th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

15 of the 89 studies in Metabolic Syndrome with a site in Spain are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Metabolic Syndrome with a site in Spain, or all of them as a file.
02

Study summary

To analyze the effects of altering the time of ingestion of participants' habitual medication (i.e., metformin, statins, ARAII/IACE) and meals around the time of exercise training (exercise fasted or fed) on the improvement of metabolic syndrome factors (hypertension, insulin sensitivity, dyslipidemia, and obesity). There will be a preliminary study of the effects of training "time-of-day" on the primary study outcomes.

Read the detailed description

Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of altering timing between exercise training, meals, and their habitual medication on the improvement in the factors that compose the metabolic syndrome (i.e., hypertension, insulin resistance, central obesity, and dyslipidemia). The main objective is to find the most productive combination between exercise training and the timing of their habitual pharmacological treatment, and meal ingestion for lowering those factors.

Methods and design: Cross-over randomized double-blinded, pretest-posttest control group experimental design. The project will be developed in a single center with the collaboration of the regional public health system (SECAM). There will be a preliminary study of the effects of training "time-of-day" on three parallel groups of individuals.

Subjects: Will be referred by their primary care physicians to our study unit or recruited by advertisements in local media.

Up to 180 subjects, all of them with metabolic syndrome will be recruited (>25% women).

Measurements:

Specifically, we will study if the cardiovascular and metabolic adaptations to aerobic training that result in amelioration of metabolic syndrome factors are potentiated by correct timming of training, meals, and medicine around exercise training time.

03

Conditions studied

  • Metabolic Syndrome, Protection Against
  • Exercise Training
  • Metformin
  • Statins
  • Angiotensin-Converting-Enzyme Inhibitor
  • Fasting, Intermittent
  • Angiotensin Hypertension

Keywords

  • Cardiorespiratory fitness
  • Insulin sensitivity
  • Dyslipidemia
  • Hypertension
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Metabolic syndrome patients diagnosed according to The International diabetes federation consensus of 2009 (Alberti, et al., Circulation).

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.

    • Respiratory failure
    • Liver o renal disease
    • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • No intervention
    NO EXERCISE TRAINING

    25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).

  • Experimental
    EXERCISE TRAINING FED

    2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).

    Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

  • Experimental
    EXERCISE TRAINING FASTED

    2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).

    Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

Interventions

  • DrugEXERCISE TRAINING WITH OR WITHOUT MEDICATION

    A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.

    Also known as: Exercise timing with respect to medication (metformin, statins, ARAII/ACEI)

06

What researchers measure

Primary outcomes

  1. Insulin sensitivity assessed using intravenous glucose tolerance test

    Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion.

    Time frame: 12 months

  2. Post-prandial lipemia assessed by an oral fat tolerance test

    Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes.

    Time frame: 12 months

  3. Blood pressure assessed by ECG-gated automated sphygmomanometer

    Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors.

    Time frame: 12 months

  4. Glycemic control assessed by 24-h continuous interstitial glucose monitoring

    Determined by a patch glucose sensor paired with a glucose monitor.

    Time frame: 36 months

Secondary outcomes

  1. Body composition.

    Determined by bioelectrical impedance to calculate body fat mass and fat free mass.

    Time frame: 12 months

  2. Body mass index

    Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2)

    Time frame: 12 months

  3. Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry

    Calculation of cardiorespitarory fitness

    Time frame: 12 months

  4. Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast

    Using indirect calorimetry and a ventilated canopy system

    Time frame: 12 months

  5. Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test.

    Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system

    Time frame: 12 months

  6. 24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry.

    To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions

    Time frame: 36 months

  7. The activity of intramuscular proteins (enzymes) involved in energetics assessed using western blots.

    Measured in skeletal muscle obtained by percutaneous muscle biopsy.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • University of Castilla-La Mancha (Exercise Physiology Lab)
    Toledo, 45071, Spain
    Recruiting
    • Ricardo Mora-Rodriguez, PhD · Contactricardo.mora@uclm.es · 92526800
    • Juan F Ortega, MD, PhD · Contactjuanfernando.ortega@uclm.es · +3492526800
    • Juan F Ortega, MD, PhD · Sub investigator
    • Ricardo Mora-Rodriguez, PhD · Principal investigator
08

References and documents

Publications

  • Ortega JF, Hamouti N, Fernandez-Elias VE, de Prada MV, Martinez-Vizcaino V, Mora-Rodriguez R. Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance. Acta Diabetol. 2014 Oct;51(5):749-55. doi: 10.1007/s00592-014-0580-4. Epub 2014 Mar 29. PubMed 24682492 ↗
  • Mora-Rodriguez R, Ortega JF, Guio de Prada V, Fernandez-Elias VE, Hamouti N, Morales-Palomo F, Martinez-Vizcaino V, Nelson RK. Effects of Simultaneous or Sequential Weight Loss Diet and Aerobic Interval Training on Metabolic Syndrome. Int J Sports Med. 2016 Apr;37(4):274-81. doi: 10.1055/s-0035-1564259. Epub 2015 Dec 14. PubMed 26667921 ↗
  • Alvarez-Jimenez L, Moreno-Cabanas A, Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals. Br J Clin Pharmacol. 2021 Mar;87(3):955-964. doi: 10.1111/bcp.14447. Epub 2020 Jul 12. PubMed 32598033 ↗
  • Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Moreno-Cabanas A. Effects of statin therapy and exercise on postprandial triglycerides in overweight individuals with hypercholesterolaemia. Br J Clin Pharmacol. 2020 Jun;86(6):1089-1099. doi: 10.1111/bcp.14217. Epub 2020 Feb 18. PubMed 31925809 ↗
  • Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Moreno-Cabanas A, Mora-Rodriguez R. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz304. doi: 10.1210/clinem/dgz304. PubMed 31875915 ↗
  • Guio de Prada V, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Moreno-Cabanas A, Mora-Rodriguez R. Women with metabolic syndrome show similar health benefits from high-intensity interval training than men. PLoS One. 2019 Dec 10;14(12):e0225893. doi: 10.1371/journal.pone.0225893. eCollection 2019. PubMed 31821339 ↗
  • Moreno-Cabanas A, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Mora-Rodriguez R. Importance of a verification test to accurately assess V̇O2 max in unfit individuals with obesity. Scand J Med Sci Sports. 2020 Mar;30(3):583-590. doi: 10.1111/sms.13602. Epub 2019 Dec 11. PubMed 31746500 ↗
  • Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Mora-Rodriguez R. Effectiveness of Aerobic Exercise Programs for Health Promotion in Metabolic Syndrome. Med Sci Sports Exerc. 2019 Sep;51(9):1876-1883. doi: 10.1249/MSS.0000000000001983. PubMed 31415443 ↗
  • Mora-Rodriguez R, Ortega JF, Ramirez-Jimenez M, Moreno-Cabanas A, Morales-Palomo F. Insulin sensitivity improvement with exercise training is mediated by body weight loss in subjects with metabolic syndrome. Diabetes Metab. 2020 Jun;46(3):210-218. doi: 10.1016/j.diabet.2019.05.004. Epub 2019 May 31. PubMed 31158474 ↗
  • Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M. Weight loss but not gains in cardiorespiratory fitness after exercise-training predicts improved health risk factors in metabolic syndrome. Nutr Metab Cardiovasc Dis. 2018 Dec;28(12):1267-1274. doi: 10.1016/j.numecd.2018.08.004. Epub 2018 Aug 23. PubMed 30459053 ↗
  • Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of intense aerobic exercise and/or antihypertensive medication in individuals with metabolic syndrome. Scand J Med Sci Sports. 2018 Sep;28(9):2042-2051. doi: 10.1111/sms.13218. Epub 2018 Jun 4. PubMed 29771450 ↗

Individual participant data

Plan to share: No — Upon reasonable request

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2024, 23 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 23 months is above that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2020
First posted
Jul 20, 2020
StartActual
Jun 7, 2022
Primary completionEst.
May 30, 2024
CompletionEst.
Dec 30, 2024
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04477590
Collaborators
Ministerio de Economía y Competitividad, Spain, Servicio de Salud de Castilla-La Mancha
Responsible party
Sponsor
First posted
Jul 20, 2020
Start date
Jun 7, 2022
Primary completion
May 30, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Aug 25, 2023

Study contacts

Ricardo Mora-Rodriguez, PhD
Contact
ricardo.mora@uclm.es
925268800
Juan F Ortega, MD, PhD
Contact
juanfernando.ortega@uclm.es
925268800
RICARDO M Mora-Rodriguez, PhD
principal investigator · University of Castilla-La Mancha

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion